Target- |
Mechanism- |
|
Originator Org.- |
|
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Not yet recruitingPhase 3 苏苏小儿止咳颗粒治疗儿童普通感冒所致咳嗽(风寒咳嗽)有效性和安全性的多中心、随机、双盲、极低剂量对照Ⅲ期临床研究
[Translation] A multicenter, randomized, double-blind, very low-dose controlled phase III clinical study on the effectiveness and safety of Susu Children's Cough Granules in treating cough caused by common cold (cold cough) in children
确证苏苏小儿止咳颗粒用于治疗 6~13 岁(6 岁≤年龄<14 岁)儿童普通感冒所致咳嗽(风寒咳嗽)缩短咳嗽病程、改善咳嗽症状的作用。
[Translation] It has been confirmed that Susu Children's Cough Relief Granules are used to treat cough (cold cough) caused by common cold in children aged 6 to 13 years old (6 years ≤ age < 14 years old), shortening the course of cough and improving cough symptoms.
苏苏小儿止咳颗粒治疗儿童普通感冒所致咳嗽(风寒咳嗽)评价其有效性和安全性的Ⅱ期临床研究
[Translation] Phase II clinical study to evaluate the effectiveness and safety of Susu Xiaoer Zhike Granules in treating cough caused by common cold (cold cough) in children
(1)探索苏苏小儿止咳颗粒治疗儿童普通感冒所致咳嗽(风寒咳嗽)缩短病程和症状改善作用。 (2)观察苏苏小儿止咳颗粒临床应用的安全性。
[Translation] (1) To explore the effect of Susu Children's Cough Relief Granules in shortening the course of illness and improving symptoms in treating cough caused by the common cold (cold cough) in children. (2) To observe the safety of Susu Children's Cough Relief Granules in clinical application.
100 Clinical Results associated with Wuhan Jungufang Technology Development Co., Ltd.
0 Patents (Medical) associated with Wuhan Jungufang Technology Development Co., Ltd.
100 Deals associated with Wuhan Jungufang Technology Development Co., Ltd.
100 Translational Medicine associated with Wuhan Jungufang Technology Development Co., Ltd.